Shane A. Olwill - Concepedia

Author

Shane A. Olwill

Also Known As

Grüner, Stefan, S A Olwill, S. Olwill, S.A. Olwill, Shane A Olwill, Shane A. Olwill, Shane A. Olwill (362078), Shane Anthony Olwill, Shane Olwill

107

Publications

Citations

H-Index

Concepts

All Affiliations

Queen's University Belfast Pieris Pharmaceuticals (United States)Washington State University The University of Texas MD Anderson Cancer Center University of Ulster

About

Shane A. Olwill is an author at Queen's University Belfast specializing in medicine, immunology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	180
2	Immunology	4	4	81
3	Cell Biology	2	2	34
4	Education	1	1	22
5	Microbiology	1	1	22

Shane A. Olwill

Publications

657

Citations

H-Index

Page 1

	Year	Citations
Antibody-Mediated Inhibition of Cathepsin S Blocks Colorectal Tumor Invasion and Angiogenesis Roberta E. Burden, Julie A. Gormley, Thomas J. Jaquin, Clinical Cancer Research	2009	108
Multiplex Immunoassay for Serological Diagnosis of <i>Mycobacterium bovis</i> Infection in Cattle Clare Whelan, Eduard A. Shuralev, Grainne O’Keeffe, Clinical and Vaccine Immunology	2008	81
The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study Julie A. Gormley, Shauna Hegarty, A O’Grady, British Journal of Cancer	2011	71
Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF Claire Ward, Diana Kuehn, Roberta E. Burden, PLoS ONE	2010	62
Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas Roberta E. Burden, Julie A. Gormley, Diana Kuehn, Biochimie OncologyCathepsin SMedicineColorectal CancerPathology	2011	50
In Vivo Visualization of MET Tumor Expression and Anticalin Biodistribution with the MET-Specific Anticalin <sup>89</sup>Zr-PRS-110 PET Tracer Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub–de Hooge, Marlon J. Hinner, Journal of Nuclear Medicine	2014	43
Sustained plasma hepcidin suppression and iron elevation by Anticalin‐derived hepcidin antagonist in cynomolgus monkey Andreas M. Hohlbaum, Hendrik Gille, Stefan Trentmann, British Journal of Pharmacology	2018	40
O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies Sarina A. Piha‐Paul, Johanna C. Bendell, Anthony Tolcher, Oral Presentations ImmunologyPathologyImmunotherapeuticsAccelerated Titration DesignImmunotherapy	2020	34
A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity Shane A. Olwill, Christian Joffroy, Hendrik Gille, Molecular Cancer Therapeutics	2013	30
525O A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies Geoffrey Y. Ku, J.C. Bendell, A. W. Tolcher, Annals of Oncology Her2-positive MalignanciesOncologyMalignant DiseaseMedicinePathology	2020	27

Page 1